Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
12 Agosto 2022 - 5:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
SEC
File Number 000-55657
NOTIFICATION
OF LATE FILING
(Check
One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form
N-CSR
For Period
Ended: June 30, 2022
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
For the
Transition Period Ended: ________________________
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If the
notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART
I -- REGISTRANT INFORMATION
Neuropathix,
Inc.
Full Name
of Registrant
Kannalife,
Inc.
Former
Name if Applicable
3805
Old Easton Road
Address
of Principal Executive Office (Street and Number)
Doylestown,
PA 18902
City, State
and Zip Code
PART
II -- RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate.)
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due date; and |
|
(c) |
The
accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III-- NARRATIVE
State
below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not
be filed within the prescribed time period. (Attach extra sheets if needed.)
Neuropathix, Inc., a Delaware corporation (the “Company”)
is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Quarterly Report”), within the
prescribed time period without unreasonable effort or expense. The Company requires additional time to finalize its financial statements
to be filed as part of the Quarterly Report. The Company intends to file the Quarterly Report within the 5-day extension period afforded
by Rule 12b-25 under the Securities Exchange Act of 1934, as amended.
PART
IV -- OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this notification
Mark
Corrao |
|
718 |
|
702-5414 |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
☒ Yes ☐ No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
☐ Yes ☒ No
If so:
attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Neuropathix, Inc.
(Name
of Registrant as Specified in Charter)
Has caused
this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Date: August
12, 2022
By /s/ Dean Petkanas
Dean Petkanas
Chief Executive
Officer
Neuropathix (CE) (USOTC:NPTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Neuropathix (CE) (USOTC:NPTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024